SANSERT Drug Patent Profile

Which patents cover Sansert, and when can generic versions of Sansert launch?

Sansert is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANSERT is methysergide maleate. Additional details are available on the methysergide maleate profile page.

Summary for SANSERT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	3,487
DailyMed Link:	SANSERT at DailyMed

Recent Clinical Trials for SANSERT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stanford University	Phase 2

See all SANSERT clinical trials

US Patents and Regulatory Information for SANSERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SANSERT	methysergide maleate	TABLET;ORAL	012516-001	Approved Prior to Jan 1, 1982		DISCN	No	No

SANSERT: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

SANSERT (filgotinib) is an orally administered JAK1 inhibitor indicated for the treatment of moderate to severely active rheumatoid arthritis (RA) in adults who have responded inadequately to, or are intolerant of, one or more disease-modifying antirheumatic drugs (DMARDs). The drug's market trajectory is influenced by clinical efficacy, safety profile, competitive landscape, and evolving regulatory guidance.

What is SANSERT's Current Market Position?

SANSERT's current market position is defined by its market penetration within the RA therapeutic area, its pricing strategy relative to competitors, and its geographic availability. As a JAK inhibitor, it competes within a class that has experienced significant growth but also faces scrutiny regarding safety.

Key Market Indicators

• Indication Focus: Primarily targets adult patients with moderate to severe RA, a segment with substantial unmet need.
• Mechanism of Action: Selectively inhibits JAK1, a key mediator in inflammatory signaling pathways implicated in RA pathogenesis.
• Therapeutic Class: Belongs to the JAK inhibitor class, alongside other approved drugs like tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq).
• Market Share: Precise market share data is proprietary and evolves, but SANSERT competes for a significant portion of the biologic and targeted synthetic DMARD market for RA.

Competitive Landscape

SANSERT competes with a range of therapeutic options for RA. The competitive environment is characterized by both similar JAK inhibitors and established biologic DMARDs.

• Direct Competitors (JAK Inhibitors):
  • Tofacitinib (Pfizer's Xeljanz): Approved in 2012, has established a significant market presence.
  • Baricitinib (Eli Lilly's Olumiant): Approved in 2017, offers another oral JAK inhibitor option.
  • Upadacitinib (AbbVie's Rinvoq): Approved in 2019, with a strong clinical profile and broad indications.
  • Abrocitinib (Pfizer's Cibinqo): Approved in 2021, another JAK1 selective inhibitor for RA.
• Indirect Competitors (Biologic DMARDs):
  • TNF inhibitors (e.g., adalimumab, etanercept, infliximab)
  • IL-6 inhibitors (e.g., tocilizumab, sarilumab)
  • B-cell depleting agents (e.g., rituximab)
• Biosimil Competition: The increasing availability of biosimil versions of established biologic DMARDs also influences market dynamics by potentially lowering treatment costs and fragmenting market share.

What are SANSERT's Clinical and Safety Performance Metrics?

Clinical efficacy and safety are paramount for drug adoption and market success. SANSERT's performance in these areas dictates its prescribing patterns and commercial viability.

Clinical Efficacy

Clinical trials have demonstrated SANSERT's efficacy in achieving key RA treatment goals.

• ACR20/50/70 Response Rates: Studies have shown significant proportions of patients achieving American College of Rheumatology (ACR) response criteria (e.g., ACR20, ACR50, ACR70), indicating substantial improvement in disease activity, pain, and physical function. For instance, the FINCH 1 trial reported ACR20 response rates for filgotinib 200 mg compared to placebo at week 24 (e.g., [Source 1]).
• DAS28 Reduction: Significant reductions in Disease Activity Score 28 (DAS28) have been observed, demonstrating overall improvement in disease control.
• Physical Function Improvement: Improvements in physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI), are a key outcome for patients.

Safety Profile

The safety profile of JAK inhibitors, including SANSERT, has been subject to regulatory review and updated prescribing information.

• Black Box Warnings: The FDA has issued black box warnings for JAK inhibitors concerning serious infections, mortality, major adverse cardiovascular events (MACE), and thrombosis. These warnings are based on post-marketing surveillance and specific clinical trial findings.
• Specific Adverse Events: Common adverse events may include upper respiratory tract infections, urinary tract infections, and elevated liver enzymes. Serious adverse events, though less frequent, can include opportunistic infections, herpes zoster, and venous thromboembolism (VTE).
• Comparative Safety: The comparative safety profile against other JAK inhibitors and biologic DMARDs is a critical factor for physicians making treatment decisions. This includes specific risks like MACE and VTE, where certain JAK inhibitors may carry different risk profiles.

What is SANSERT's Regulatory Status and Pricing Strategy?

Regulatory approvals and reimbursement decisions directly impact market access and financial performance. Pricing strategies are designed to reflect value and competitive positioning.

Regulatory Approvals and Restrictions

• Initial Approvals: SANSERT received approvals in various regions based on specific clinical trial data. For example, it gained approval in the European Union for RA.
• FDA Decision: In the United States, the FDA's review process for filgotinib (under the brand name GILEAD) faced challenges, particularly concerning cardiovascular safety and thrombosis risks, leading to a narrower indication or specific restrictions compared to other regions. The FDA's decision-making process often incorporates risk evaluation and mitigation strategies (REMS).
• Labeling Updates: Regulatory bodies globally have updated labeling for JAK inhibitors to reflect emerging safety data, including revised warnings and precautions.

Pricing and Reimbursement

• Wholesale Acquisition Cost (WAC): The WAC for SANSERT is set by the manufacturer, Gilead Sciences. This price is a starting point for negotiations with payers.
• Payer Negotiations: Reimbursement rates and formulary placement are determined through negotiations with pharmacy benefit managers (PBMs) and insurance providers. These negotiations are influenced by clinical trial data, comparative effectiveness studies, and the drug's overall value proposition.
• Market Access: Successful market access requires favorable formulary placement, reduced prior authorization requirements, and competitive co-pays for patients.

Financial Trajectory Factors

• Sales Performance: Actual sales figures are reported by Gilead Sciences in their quarterly and annual financial reports. These reports provide insights into revenue generation from SANSERT.
• R&D Investment: Ongoing investment in clinical trials, post-marketing studies, and potential new indications affects the drug's long-term financial outlook.
• Patent Expirations: The duration of patent exclusivity is a critical determinant of long-term profitability. The expiration of key patents opens the door for generic or biosimilar competition, which significantly impacts revenue.

What are SANSERT's Revenue and Market Forecasts?

Forecasting SANSERT's revenue requires an analysis of current sales trends, market growth projections, and potential future market penetration.

Historical Revenue Performance

Gilead Sciences reports revenue for its immunology segment, which includes SANSERT. Analyzing year-over-year growth rates for this segment provides insight into the drug's commercial traction. Specific revenue figures for SANSERT are often aggregated within broader product categories.

Market Growth Drivers and Restraints

• Drivers:
  • Increasing RA prevalence globally.
  • Growing patient and physician acceptance of targeted therapies.
  • Expansion into new geographic markets.
  • Potential for new indications or combination therapies.
• Restraints:
  • Safety concerns associated with JAK inhibitors, leading to regulatory restrictions and physician caution.
  • Intense competition from established biologics and other JAK inhibitors.
  • The advent of biosimil competition for older biologics.
  • Pricing pressures from payers and healthcare systems.

Projected Market Size and Growth

The global RA drug market is projected to continue its growth trajectory, driven by factors such as an aging population and an increase in diagnosis rates. Within this market, targeted therapies like JAK inhibitors are expected to capture a larger share.

• Projected Growth Rate: Market research firms project a compound annual growth rate (CAGR) for the RA market, with specific forecasts for the JAK inhibitor segment varying based on the assumptions of regulatory actions, safety perceptions, and competitive dynamics.
• Market Share Projections: Forecasts for SANSERT's market share will depend on its ability to differentiate itself on efficacy, safety, and value, particularly in regions where it has broader approval and market access.

What are the Key Future Opportunities and Challenges for SANSERT?

The future of SANSERT is contingent on its ability to navigate evolving market dynamics, capitalize on unmet needs, and mitigate emerging risks.

Opportunities

• Expanding Indications: Pursuing approvals in other inflammatory autoimmune diseases where JAK pathways are implicated, such as psoriatic arthritis or inflammatory bowel disease, could significantly broaden its market.
• Combination Therapies: Investigating synergistic effects when used in combination with other RA treatments, provided safety profiles are manageable.
• Geographic Expansion: Securing regulatory approvals and market access in emerging markets can unlock substantial growth potential.
• Real-World Evidence Generation: Continued generation of robust real-world evidence (RWE) can reinforce clinical benefits and address safety concerns, potentially influencing physician prescribing habits and payer policies.

Challenges

• Regulatory Scrutiny: Ongoing monitoring and potential further regulatory actions related to the safety of JAK inhibitors remain a significant concern.
• Competitive Intensity: The high level of competition within the RA treatment landscape necessitates continuous innovation and effective market differentiation.
• Pricing and Reimbursement Pressures: Sustained pressure from payers to demonstrate cost-effectiveness and value will continue to influence pricing and market access strategies.
• Physician and Patient Education: Effectively communicating SANSERT's risk-benefit profile to healthcare providers and patients is crucial for appropriate utilization and to mitigate safety concerns.

Key Takeaways

SANSERT operates in a highly competitive and regulated RA market. Its success hinges on its demonstrated clinical efficacy, a carefully managed safety profile, and strategic pricing and market access. The drug faces significant competition from other JAK inhibitors and established biologics, alongside the ever-present threat of evolving regulatory guidance concerning JAK inhibitors. Future growth opportunities lie in expanding indications and leveraging real-world evidence, while key challenges include navigating stringent regulatory oversight and intense competitive pressures.

Frequently Asked Questions

What is the primary therapeutic target of SANSERT?

SANSERT is designed to selectively inhibit Janus kinase 1 (JAK1).

In which patient population is SANSERT approved for rheumatoid arthritis?

SANSERT is approved for adult patients with moderate to severely active rheumatoid arthritis who have had an inadequate response to, or are intolerant of, one or more disease-modifying antirheumatic drugs.

What are the main safety concerns associated with JAK inhibitors like SANSERT?

Key safety concerns for JAK inhibitors include serious infections, major adverse cardiovascular events (MACE), thrombosis, and mortality.

How does SANSERT compare to other JAK inhibitors in the RA market?

SANSERT competes directly with other JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib, with differentiation often based on specific efficacy endpoints, safety profiles, and regulatory indications.

What factors are critical for SANSERT's future market growth?

Future market growth for SANSERT depends on expanding its approved indications, generating robust real-world evidence, securing broad market access, and effectively managing its safety profile in the face of ongoing regulatory scrutiny and intense competition.

---

Citations

[1] Data on file. (n.d.). FINCH 1 trial results. Gilead Sciences. (Specific publication or press release details would be inserted here if available)